ORIGINAL RESEARCH article
Front. Health Serv.
Sec. Health Policy and Management
Volume 5 - 2025 | doi: 10.3389/frhs.2025.1583104
This article is part of the Research TopicAntibiotic consumption in hospitals and its impact on bacterial resistanceView all articles
Analysis of the Use Effect of Antibacterial Drugs in the Department of Pediatrics under the National Centralized Drug Procurement
Provisionally accepted
- 1Xuzhou Children's Hospital, Xuzhou, Jiangsu Province, China
- 2Suqian First People's Hospital, Suqian, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
To investigate the impact of the National Centralized Drug Procurement (NCDP) policy on the utilization patterns and safety of antibacterial drugs in pediatric patients. Methods: Data on antibacterial drug use and adverse drug reactions (ADRs) from 2021 (pre-NCDP implementation) and 2024 (post-NCDP implementation) were extracted from the pediatric department of Suqian First Hospital. Key indicators analyzed included: defined daily doses per capita, daily drug cost per capita, antimicrobial use density, proportion of NCDP drugs in total antibacterial varieties and consumption, and ADR incidence. Results: The proportion of NCDP antibacterial varieties increased significantly from 12.90% (2021) to 78.94% (2024), and their consumption share rose from 10.80% to 68.85% (both P < 0.001). The daily drug cost per capita decreased by 36.1% (from 85.9 to 54.9), and antimicrobial use density decreased by 11.8 (from 40.9 to 29.1). No significant differences were observed in defined daily doses per capita (1.6 vs. 1.9) or ADR incidence (0.53% vs. 0.47%, P > 0.05).The NCDP policy effectively reduced the economic burden of pediatric antibacterial therapy, optimized prescribing patterns without compromising safety, and supported the rational use of antibiotics in children. These findings underscore the policy's role in promoting cost-effective of pediatric infections.
Keywords: National Centralized Drug Procurement, Children, Antibacterial drugs, Medication analysis, Adverse Reactions, Use intensity of antibacterial drugs
Received: 10 Mar 2025; Accepted: 22 Apr 2025.
Copyright: © 2025 Xu, Zhang and Yun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Youwen Zhang, Suqian First People's Hospital, Suqian, 223835, Jiangsu Province, China
Yi Yun, Suqian First People's Hospital, Suqian, 223835, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.